GO
Loading...

Biotechnology

More

  • Time to buy biotech?     Wednesday, 13 Aug 2014 | 4:38 PM ET

    Barbara Ryan, FTI Consulting, discusses the tremendous amount of innovation within in the biotech sector and why the segment is attractive.

  • Biotechs race for Ebola cure     Monday, 11 Aug 2014 | 5:30 PM ET

    CNBC's Meg Tirrell looks at companies in the early stages of Ebola drug and vaccine trials.

  • Merck & Pfizer beat the Street     Tuesday, 29 Jul 2014 | 10:14 AM ET

    CNBC's Meg Tirrell reports both Merck and Pfizer beat earnings expectations amid patent expirations.

  • What's coming in biotech?     Wednesday, 23 Jul 2014 | 2:15 PM ET

    "The market is very favorable for biotech these days," says Les Funtleyder, Bluecloud Healthcare, in discussing growth in the space.

  • CNBC's Meg Tirrell speaks to Dr. George Scangos, Biogen Idec CEO, about the company's Q2 earnings surge, drug pipeline, and America's tax code. Scangos says we need a corporate tax rate that is competitive with rest of the world and a territorial tax system.

  • Faber Report: Puma Biotech surges     Wednesday, 23 Jul 2014 | 10:39 AM ET

    CNBC's David Faber reports Puma Biotechnology surges on positive results for a breast cancer drug.

  • Analyst calls out Yellen's biotech comments     Friday, 18 Jul 2014 | 12:45 PM ET

    Mark Schoenbaum, ISI Group, explains why his views differ from Janet Yellen on whether the biotech sector is forming a bubble.

  • How will Yellen's comments impact US stocks?     Tuesday, 15 Jul 2014 | 11:34 PM ET

    Dodge Dorland, Chairman & Chief Investment Officer at Landor & Fuest Capital Managers, says social media and biotech stocks may see more downside in the short run.

  • Fed hits social, tech stocks     Tuesday, 15 Jul 2014 | 3:02 PM ET

    After Janet Yellen's comments on stretched valuations in the social media and biotech sectors, CNBC's Seema Mody looks at what stocks are taking the biggest hit.

  • Next global epidemic?     Tuesday, 15 Jul 2014 | 1:40 PM ET

    CNBC's Meg Tirrell reports which biotech companies are working on what analysts say could be the next big biotech catalyst known as NASH, or nonalcoholic steatohepatitis.

  • Acorda 'firmly on the side of research': CEO     Thursday, 10 Jul 2014 | 8:43 AM ET

    Ron Cohen, Acorda Therapeutics CEO, discusses merger activity in the pharma sector and whether his company is planning an acquisition.

  • Biotech buys right now     Tuesday, 8 Jul 2014 | 5:46 PM ET

    The S&P Biotech ETF is down 7 percent this week. Robyn Karnauskas, Deutsche Bank biotechnology director, shares her large and small cap picks.

  • Rough day for biotech     Tuesday, 8 Jul 2014 | 1:06 PM ET

    CNBC's Meg Tirrell reports biotech stocks are performing lower than the broader markets.

  • Protect yourself from fake medicine     Monday, 7 Jul 2014 | 1:55 PM ET

    CNBC's Scott Cohn follows up on his investigation into the high cost of prescription drugs and reports how consumers can protect themselves from getting fake medicine.

  • Incubating biotech's boom     Thursday, 3 Jul 2014 | 1:11 PM ET

    Quincy College in Massachusetts created a two year program to fill bio-manufacturing technician positions. CNBC's Mary Thompson reports how the school is fueling job growth.

  • Prescription drugs: Risk vs. cost     Wednesday, 2 Jul 2014 | 1:46 PM ET

    Due to the high cost of prescription drugs, many in the U.S. look overseas to save money. CNBC's Scott Cohn discusses if people are putting themselves at risk or beating big drug companies at their own game.

  • *Roche adds to breast cancer drug offering with Seragon. Roche is looking to bolster its offering of breast cancer drugs with the purchase. Since walking away from a $6.8 billion deal to buy U.S gene sequencing company Illumina in 2012 Roche has eschewed multi-billion deals and instead snapped up a couple of smaller diagnostic companies so far this year.

  • Best time to buy Celgene, Vertex & more     Friday, 27 Jun 2014 | 12:17 PM ET

    The biotech ETF soared 67 percent in 2013, but has since been bumpy. Discussing winning and losing stocks in the industry, with Mark Schoenebaum, ISI pharma/biotech analyst.

  • Bone disease breakthrough     Thursday, 26 Jun 2014 | 5:45 PM ET

    Emil Kakkis, Ultragenyx founder & CEO, discusses the beginning of its drug KRN23's phase 2 pediatric study to treat 30 kids with bone disorder X-linked hypophosphatemia (XLH).

  • Vertex CEO on big cystic fibrosis breakthrough     Tuesday, 24 Jun 2014 | 3:37 PM ET

    CNBC's Meg Tirrell speaks to Vertex Pharmaceuticals CEO Dr. Jeffrey Leiden, about its promising two-drug cystic fibrosis treatment, and what it means for sufferers of the disease. Leiden also explains what goes into the pricing of an "orphan drug."